{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:51:34Z","timestamp":1791154294107,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-026-03206-9","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:35:40Z","timestamp":1791023740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057)"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"umin000046700","registry":"10.18810\/umin-japan"}],"author":[{"given":"Kohei","family":"Kushiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tsukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Tozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kyoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruo","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yokouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minehiko","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kanaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Takashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-3153","authenticated-orcid":false,"given":"Hajime","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"3206_CR1","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"3206_CR2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"key":"3206_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2340\/1651-226X.2024.34876","volume":"63","author":"M Borg","year":"2024","unstructured":"Borg M, T\u00f8nnesen H, Ibsen R et al (2024) Lung cancer: a nationwide analysis of sex and age incidence trends from 1980 to 2022. Acta Oncol 63:526\u2013531. https:\/\/doi.org\/10.2340\/1651-226X.2024.34876","journal-title":"Acta Oncol"},{"key":"3206_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/jgs.15786","volume":"67","author":"J Lockett","year":"2019","unstructured":"Lockett J, Sauma S, Radziszewska B et al (2019) Adequacy of inclusion of older adults in NIH-funded phase III clinical trials. J Am Geriatr Soc 67:218\u2013222. https:\/\/doi.org\/10.1111\/jgs.15786","journal-title":"J Am Geriatr Soc"},{"key":"3206_CR5","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","volume":"18","author":"FV Fossella","year":"2000","unstructured":"Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-small Cell Lung Cancer Study Group. J Clin Oncol 18:2354\u20132362. https:\/\/doi.org\/10.1200\/JCO.2000.18.12.2354","journal-title":"J Clin Oncol"},{"key":"3206_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665\u2013673. https:\/\/doi.org\/10.1016\/S0140-6736(14)60845-X","journal-title":"Lancet"},{"key":"3206_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","volume":"14","author":"G Scagliotti","year":"2009","unstructured":"Scagliotti G, Hanna N, Fossella F et al (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14:253\u2013263. https:\/\/doi.org\/10.1634\/theoncologist.2008-0232","journal-title":"Oncologist"},{"key":"3206_CR8","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1093\/annonc\/mdx419","volume":"28","author":"H Nokihara","year":"2017","unstructured":"Nokihara H, Lu S, Mok TSK et al (2017) Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 28:2698\u20132706. https:\/\/doi.org\/10.1093\/annonc\/mdx419","journal-title":"Ann Oncol"},{"key":"3206_CR9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jtho.2021.03.027","volume":"16","author":"Y Yoneshima","year":"2021","unstructured":"Yoneshima Y, Morita S, Ando M et al (2021) Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol 16:1523\u20131532. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.027","journal-title":"J Thorac Oncol"},{"key":"3206_CR10","doi-asserted-by":"publisher","DOI":"10.2196\/26425","volume":"7","author":"M George","year":"2021","unstructured":"George M, Smith A, Sabesan S et al (2021) Physical comorbidities and their relationship with cancer treatment and its outcomes in older adult populations: systematic review. JMIR Cancer 7:e26425. https:\/\/doi.org\/10.2196\/26425","journal-title":"JMIR Cancer"},{"key":"3206_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107426","volume":"186","author":"Y Sakata","year":"2023","unstructured":"Sakata Y, Saito G, Sakata S et al (2023) Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP). Lung Cancer (Amsterdam, Netherlands) 186:107426. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107426","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"3206_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100730","volume":"36","author":"NM Carroll","year":"2023","unstructured":"Carroll NM, Eisenstein J, Burnett-Hartman AN et al (2023) Uptake of novel systemic therapy: real world patterns among adults with advanced non-small cell lung cancer. Cancer Treat Res Commun 36:100730. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100730","journal-title":"Cancer Treat Res Commun"},{"key":"3206_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11523-024-01045-0","volume":"19","author":"K Onoi","year":"2024","unstructured":"Onoi K, Yamada T, Morimoto K et al (2024) Efficacy and safety of docetaxel plus ramucirumab for patients with pretreated advanced or recurrent non-small cell lung cancer: focus on older patients. Target Oncol 19:411\u2013421. https:\/\/doi.org\/10.1007\/s11523-024-01045-0","journal-title":"Target Oncol"},{"key":"3206_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00280-020-04055-7","volume":"85","author":"O Yamaguchi","year":"2020","unstructured":"Yamaguchi O, Imai H, Minemura H et al (2020) Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemother Pharmacol 85:761\u2013771. https:\/\/doi.org\/10.1007\/s00280-020-04055-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"3206_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2169\/internalmedicine.3649-24","volume":"64","author":"S Wasamoto","year":"2025","unstructured":"Wasamoto S, Imai H, Tsuda T et al (2025) Efficacy and safety of first-line pembrolizumab plus platinum and pemetrexed in elderly patients with non-squamous non-small-cell lung cancer. Intern Med 64:55\u201364. https:\/\/doi.org\/10.2169\/internalmedicine.3649-24","journal-title":"Intern Med"},{"key":"3206_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807575","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang Z, Chen Y, Wang Y et al (2022) Pembrolizumab plus chemotherapy versus chemotherapy monotherapy as a first-line treatment in elderly patients (\u226575 years old) with non-small-cell lung cancer. Front Immunol 13:807575. https:\/\/doi.org\/10.3389\/fimmu.2022.807575","journal-title":"Front Immunol"},{"key":"3206_CR17","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.3390\/curroncol28050357","volume":"28","author":"HAI Grosjean","year":"2021","unstructured":"Grosjean HAI, Dolter S, Meyers DE et al (2021) Effectiveness and safety of first-line pembrolizumab in older adults with PD-L1 positive non-small cell lung cancer: a retrospective cohort study of the Alberta immunotherapy database. Curr Oncol 28:4213\u20134222. https:\/\/doi.org\/10.3390\/curroncol28050357","journal-title":"Curr Oncol"},{"key":"3206_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100397","volume":"3","author":"Y Goto","year":"2022","unstructured":"Goto Y, Tamura A, Matsumoto H et al (2022) First-line pembrolizumab monotherapy for advanced NSCLC with programmed death-ligand 1 expression greater than or equal to 50%: real-world study including older patients in Japan. JTO Clin Res Rep 3:100397. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100397","journal-title":"JTO Clin Res Rep"},{"key":"3206_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00432-019-03072-1","volume":"146","author":"H Imai","year":"2020","unstructured":"Imai H, Wasamoto S, Yamaguchi O et al (2020) Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged \u2265 75 years) with non-small cell lung cancer. J Cancer Res Clin Oncol 146:457\u2013466. https:\/\/doi.org\/10.1007\/s00432-019-03072-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"3206_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamaoncol.2023.6277","volume":"10","author":"Y Tsukita","year":"2024","unstructured":"Tsukita Y, Tozuka T, Kushiro K et al (2024) Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer. JAMA Oncol 10:439\u2013447. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6277","journal-title":"JAMA Oncol"},{"key":"3206_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"3206_CR22","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1111\/1759-7714.13622","volume":"11","author":"H Imai","year":"2020","unstructured":"Imai H, Minemura H, Kishikawa T et al (2020) Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged \u226575 years) with non-small cell lung cancer: a retrospective analysis. Thorac Cancer 11:2867\u20132876. https:\/\/doi.org\/10.1111\/1759-7714.13622","journal-title":"Thorac Cancer"},{"key":"3206_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/CIA.S97363","volume":"11","author":"F Jin","year":"2016","unstructured":"Jin F, Zhu H, Shi F et al (2016) A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma. Clin Interv Aging 11:167\u2013173. https:\/\/doi.org\/10.2147\/CIA.S97363","journal-title":"Clin Interv Aging"},{"key":"3206_CR24","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1200\/JCO.2006.06.7835","volume":"24","author":"GJ Weiss","year":"2006","unstructured":"Weiss GJ, Langer C, Rosell R et al (2006) Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 24:4405\u20134411. https:\/\/doi.org\/10.1200\/JCO.2006.06.7835","journal-title":"J Clin Oncol"},{"key":"3206_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cllc.2011.06.008","volume":"13","author":"H Asahina","year":"2012","unstructured":"Asahina H, Sekine I, Horinouchi H et al (2012) Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 13:39\u201343. https:\/\/doi.org\/10.1016\/j.cllc.2011.06.008","journal-title":"Clin Lung Cancer"},{"key":"3206_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.4103\/0973-1482.146092","volume":"11","author":"AM Tatli","year":"2015","unstructured":"Tatli AM, Arslan D, Uysal M et al (2015) Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer. J Cancer Res Ther 11:805\u2013809. https:\/\/doi.org\/10.4103\/0973-1482.146092","journal-title":"J Cancer Res Ther"},{"key":"3206_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/1759-7714.12463","volume":"8","author":"H Imai","year":"2017","unstructured":"Imai H, Kaira K, Minato K (2017) Clinical significance of post-progression survival in lung cancer. Thorac Cancer 8:379\u2013386. https:\/\/doi.org\/10.1111\/1759-7714.12463","journal-title":"Thorac Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03206-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:01:42Z","timestamp":1791151302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03206-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":27,"alternative-id":["3206"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03206-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kohei Kushiro reported receiving personal fees from Chugai Pharmaceutical, Merck Biopharm, Takeda Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan, Kyowa Kirin, and Teijin Healthcare outside the submitted work. Dr. Yoko Tsukita reported receiving personal fees from AstraZeneca, Eli Lilly, MSD, Chugai Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo, Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, Amgen, Ono Pharmaceutical, and Kyowa Kirin outside the submitted work. Dr. Takehiro Tozuka reported receiving personal fees from AstraZeneca and Chugai Pharmaceutical outside the submitted work. Dr. Shinobu Hosokawa has nothing to disclose. Dr. Toshiyuki Sumi reported receiving personal fees from Ono Pharmaceutical, AstraZeneca, and Boehringer Ingelheim Japan outside the submitted work. Dr. Mao Uematsu has nothing to disclose. Dr. Osamu Honjo reported receiving personal fees from Bristol Myers Squibb, Eli Lilly, Daiichi Sankyo, Chugai Pharmaceutical, and MSD outside the submitted work. Dr. Ou Yamaguchi reported receiving personal fees from Ono Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Nippon Kayaku, MSD, Kyowa Kirin, Johnson & Johnson Innovative Medicine, Chugai Pharmaceutical, Eli Lilly, Takeda Pharmaceutical, Daiichi Sankyo, Novartis Pharma, and Amgen outside the submitted work. Dr. Hiroyuki Kyoyama has nothing to disclose. Dr. Kyoji Tsurumi has nothing to disclose. Dr. Yohei Suzuki has nothing to disclose. Dr. Daisuke Ishikawa reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical, and Kyowa Kirin outside the submitted work. Dr. Naruo Yoshimura has nothing to disclose. Dr. Naoko Matsumoto has nothing to disclose. Dr. Hiromi Nagashima has nothing to disclose. Dr. Ryotaro Kida has nothing to disclose. Dr. Hiroshi Yokouchi reported receiving personal fees from AstraZeneca and Chugai Pharmaceutical outside the submitted work and research funding from AstraZeneca, Bristol-Myers Squibb, Sanofi, Daiichi Sankyo, Amgen, AbbVie, Takeda Pharmaceutical, Chugai Pharmaceutical, and MSD. Dr. Minehiko Inomata reported receiving personal fees from AstraZeneca, Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, and Boehringer Ingelheim Japan outside the submitted work. Dr. Nobuhiro Kanaji has nothing to disclose. Dr. Taichi Takashina reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Bristol-Myers Squibb, KYORIN Pharmaceutical, Nippon Kayaku, and Otsuka Holdings outside the submitted work. Dr. Satoshi Morita reported receiving personal fees from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MSD, and Ono Pharmaceutical outside the submitted work. Dr. Kunihiko Kobayashi reported receiving consulting fees from Daiichi Sankyo and UCB Japan and personal fees from AstraZeneca and Janssen Pharmaceutical and holds Japanese patent No. 7422498. Dr. Hajime Asahina reported receiving personal fees from AstraZeneca, Eli Lilly, Ono Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, and MSD outside the submitted work and research funding from AstraZeneca.","order":1,"name":"Ethics","label":"Conflict of Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Tohoku University Hospital (2021\u20131-989; approved on January 26, 2022).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for the use of medical data was obtained using an opt-out approach.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}